CV Therapeutics Announces Presentations at the American College of Cardiology 58th Annual Scientific Session
16 Marzo 2009 - 2:01PM
Marketwired
CV Therapeutics, Inc. (NASDAQ: CVTX) announced today that four
abstracts on clinical and preclinical studies have been accepted
for presentation at the American College of Cardiology (ACC) 58th
Annual Scientific Session, which will be held in Orlando, FL on
March 29 - 31, 2009.
Poster Sessions
Increased CO2 Levels Augment Late Sodium Current and Cause
Torsade de Pointes; Poster, Sunday, March 29, 9:30 a.m. EDT
Ranolazine, a Late Sodium Current Inhibitor, Markedly Reduces
Ventricular Arrhythmias in a Model of Coronary
Occlusion/Reperfusion; Poster, Sunday, March 29, 9:30 a.m. EDT
Ventricular Arrhythmias Following Non-ST Segment Elevation ACS
and the Relationship with Sudden Cardiac Death in the MERLIN
TIMI-36 Trial; Poster, Monday, March 30, 9:30 a.m. EDT
Blunting of the Heart Rate Response to Adenosine and Regadenoson
in Relation to Hyperglycemia and the Metabolic Syndrome in the
ADVNACE MPI Trials; Poster, Tuesday, March 31, 9:30 a.m. EDT
Additional information regarding the ACC 58th Annual Scientific
Sessions can be accessed at
http://acc09.acc.org/Pages/default.aspx.
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California,
is a biopharmaceutical company primarily focused on applying
molecular cardiology to the discovery, development and
commercialization of novel, small molecule drugs for the treatment
of cardiovascular diseases. CV Therapeutics Europe Ltd. is the
company's European subsidiary based in the United Kingdom.
CV Therapeutics' approved products in the United States include
Ranexa� (ranolazine extended-release tablets), indicated for the
treatment of chronic angina, and Lexiscan� (regadenoson) injection
for use as a pharmacologic stress agent in radionuclide myocardial
perfusion imaging in patients unable to undergo adequate exercise
stress.
Except for the historical information contained herein, the
matters set forth in this press release, including statements as to
research and development and commercialization of products, are
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially,
including operating losses and fluctuations in operating results;
capital requirements; regulatory review and approval of our
products; the conduct and timing of clinical trials;
commercialization of products; market acceptance of products;
product labeling; concentrated customer base; reliance on strategic
partnerships and collaborations; uncertainties in drug development;
uncertainties regarding intellectual property and other risks
detailed from time to time in CV Therapeutics' SEC reports,
including its Annual Report on Form 10-K for the year ended
December 31, 2008. CV Therapeutics disclaims any intent or
obligation to update these forward-looking statements.
Investor and Media Contact John Bluth Executive Director
Corporate Communications & Investor Relations CV Therapeutics,
Inc. (650) 384-8850
CV Therapeutics (NASDAQ:CVTX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
CV Therapeutics (NASDAQ:CVTX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024